Top Oncology Solutions Companies - oncology Companies
healthcaretechoutlook
OncoGenesis: Upgrading the Cervical Cancer Screening Paradigm

Top 10 Oncology Solutions Companies - 2022

Technological advances within the last few years have altered the whole oncology space. The sudden increase in chronic diseases like cancer have forced oncology solutions providers to introduce better and safer alternatives to conventional treatments. As a result, a record number of new drugs have acquired regulatory authorization. Modern treatments like immunotherapy and gene therapy have perpetually transformed the way healthcare institutions approach cancer treatment. These advancements in biopharmaceuticals were only made possible by leveraging robust technological solutions like artificial intelligence and big data analytics.

The use of AI and Big Data Analytics in the surgical processes is gradually gaining momentum. The non-invasive surgical interventions have also benefited from robotics and enhanced imaging techniques that can minimize the risk of complications. Moreover, recent advancements in Telemedicine space have helped patients in remote areas who are immunocompromised or are unable to access medical care in a traditional setting. Further, the incorporation of modern technologies will bring accuracy, flexibility, and cost-effectiveness into the healthcare sector. While modern technological programs are rapidly being integrated into oncologic research, work remains to be done to translate these studies into real-world, clinically meaningful applications.

In this edition of Healthcare Tech Outlook, we have compiled a list of the 10 most promising oncology solutions providers. The list comprises prominent organizations in the industry that solve challenges in the oncology arena by leveraging the current trends.

We present to you Healthcare Tech Outlook’s, “Top 10 Oncology Solutions Providers – 2022.”

    Breakthrough Oncology Solution Provider

  • OncoGenesis is on a mission to provide tools that help expand access to screening and detect cervical disease and its progression. The company’s Our iPap® Personal Cervical Sample Collector and CRISPR-enabled point-of-care (POC) Biomarker Screening System expand access to increase screening participation and the biomarkers provide greater clinical information to guide treatment decisions. OncoGenesis' iPap is the first cervical cell collector that enables women to conveniently self-collect a cervical specimen adequate for co-testing both HPV and cytology testing. The company’s biomarker screen detects cervical disease, unlike HPV screening that only determines the presence of the virus, which is cleared by 80 percent of women within two years.

    oncogenx.com

    Top Oncology Solutions Companies

  • Clearwave provides practices with the tools, technologies and expertise they need to automate, streamline and simplify administrative processes across the patient engagement journey, such as patient scheduling and check-in. With the Clearwave platform, patients can self-schedule an appointment, verify insurance eligibility, clear payment balances and co-pays, complete clinical intake and check in via mobile phone, kiosk or online portal without staff involvement. This patient independence frees staff from tedious and burdensome frontdesk administrative work so they can apply that time to higher-value patientsupport activities.

    www.clearwaveinc.com

  • Elucent Medical provides advanced surgical navigation technology to precisely locate soft tissue cancerous growth in real-time during surgery. The company offers surgical oncologists an intelligent soft tissue marker SmartClip™ and stereotactic surgical navigation to enable high-precision tumor site detection throughout the surgical removal procedure. The company’s EnVisioTM Platform technology improves clinical outcomes for breast cancer patients and is designed to offer similar surgical navigation used in other oncology specialties that guide oncologists in identifying the precise 3D location of the cancerous growth with the state-of-the-art surgical navigation system and precision-guided tools.

    elucentmedical.com

  • Founded in 2013, PPS is a social enterprise of the Cancer Support Community (CSC), the largest nonprofit employer of oncology mental health professionals in the United States that licenses its state-of-the-art psychosocial technology and programming. They work with patients, healthcare providers, and community organizations to deliver distress screening and other assessments via their digital platform. Their flagship solution, PPS' Cancer Support Source® is a screening solution delivered over their SaaS platform, called My Care Report—which can integrate with any EMR or work as a standalone platform. It allows for multiple surveys and assessments to be launched for patients or caregivers at home, in clinics, or offices. A hospital or a cancer center can license the tool and use it prescriptively.

    www.patientplanningservices.com

  • AngioDynamics

    AngioDynamics

    AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine. These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes. We understand and accept the important responsibility that AngioDynamics and its products have in a patient’s care and adhere to the highest standards of quality and compliance in everything that we do. We value the importance of trust and honesty in all relationships and are deeply committed to improving patient care by ethically serving our customers, shareholders and employees. We add significant value in every interaction with our customers by providing unsurpassed service and the highest quality, best performing products and dedicate ourselves to the pursuit of innovation with a team who endeavors to be the best and the brightest in the medical device industry.

  • Axion BioSystems

    Axion BioSystems

    At Axion BioSystems, our goal is to provide advanced live-cell assay systems that allow you to noninvasively evaluate your cells. Whether tracking the growth and death of cancer cells or monitoring the intricate, electrically active behavior of excitable cells such as neurons and cardiomyocytes, our innovative and award-winning products are designed to help you investigate the function of your cells with a range of easy-to-use in vitro assays. Axion initially launched the first commercial multiwell MEA system, the MaestroTM, a next-generation noninvasive instrument that measures functional electrical signals from brain and heart cells. We’ve continued to expand on this advanced technology with our introduction of the Maestro Z, a platform that provides functional measures of cell growth and has specific applications in immuno-oncology and immunotherapies. The acquisition of CytoSMART Technologies expands our capabilities into live-cell imaging with systems like the CytoSMART Omni—an automated imaging microscope that enables new insights into cellular health, viability, colony formation, migration, and cellular responses to external stimuli. Axion’s steady pipeline of innovative, industry-leading products increase throughput, functionality, and information for academic, biotechnology, and pharmaceutical researchers. Our commitment to your discoveries also includes expert knowledge of the biological applications our technology enables.

  • Mevion Medical Systems

    Mevion Medical Systems

    Mevion Medical Systems is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. Mevion Medical Systems exists to deliver on the promise of proton therapy for cancer centers, clinicians and patients worldwide. We invented compact proton therapy and are continuing to transform the industry and patient care with the MEVION S250 Series™.

  • nRichDX

    nRichDX

    nRichDX Inc, based in Irvine, CA is an emerging leader in the liquid biopsy sample prep market, delivering up to 75X more target material (ctDNA, CTCs, exosomes, etc.) than existing sample prep systems for molecular testing. The patented Revolution™ System is the first high-yield, IVD liquid biopsy sample prep platform that can process sample volumes from 1 mL-50 mL and offers a single solution for multiple specimen types and targets. nRichDX solves one of precision medicine’s greatest problems - - inaccurate diagnostic results for up to 50% of liquid biopsy-based molecular diagnostic tests (NGS, PCR, Micro Array, etc.) due to a lack of target material. The Revolution platform greatly enhances test sensitivity and enables high confidence test results that promote earlier detection, monitoring, timely treatment and optimal patient outcomes.

  • Sumitomo Pharma Oncology

    Sumitomo Pharma Oncology

    Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer Research Unit and Oncology Clinical Development Unit, will collectively be known as Sumitomo Pharma Oncology or SMP Oncology. SMP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Our robust and diverse pipeline spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology. SMP Oncology encompasses discovery research, external innovation, clinical development and commercialization. The company has teams in Lehi, Utah, Tokyo and Osaka, Japan as well as Cambridge, Massachusetts. At SMP Oncology, we believe in the power of science – and our people – to usher in breakthrough innovation that will positively impact patients with cancer today and for generations to come.

  • Sun Nuclear Corporation

    Sun Nuclear Corporation

    Sun Nuclear, part of Mirion Technologies, provides innovative solutions for Radiation Therapy and Diagnostic Imaging centers. Our mission is to enable healthier lives by improving the avoidance, detection and treatment of cancer. More than 5,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, we aim to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety.

  • Varian Medical Systems

    Varian Medical Systems

    At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight.